Research Projects

TNBC, an aggressive subtype of breast cancer, lacks estrogen and progesterone receptors and the human epidermal growth factor receptor gene. Current therapeutic options focus on targeting TNBC cells, but conventional chemotherapeutic medications can spare TNBC stem cells, increasing the risk of tumor relapse. A successful strategy should target both TNBC cells and TNBCsCs simultaneously. The role of sP or tNK-1R and COX-2 enzyme in TNBC progression is well-established. The study hypothesizes that combining Aprepitant and Etoricoxib could introduce a new strategy in chemotherapy with superior anti-TNBC potential. Polymeric nanoparticles (PNPs) have been investigated as nano drug delivery systems due to their biodegradability, biocompatibility, and non-toxic properties. Engineering PNPs with TNBC-specific markers like CD44 can enhance the therapeutic efficacy of loaded drugs while minimizing toxic effects.